Stereotaxis’ CEO said the company has been “hampered clinically, commercially and strategically” by its prior dependence on a J&J catheter.

Sepsis scores are not validated in pregnancy; delays increase mortality. If intrauterine infection is suspected, induce ...

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac insights ...

A first-in-human percutaneous aorto-coronary bypass procedure, dubbed "VECTOR," was used to prevent coronary obstruction ...

Austin, Texas, United States, January 5th, 2026, FinanceWire HeartBeam (NASDAQ: BEAT), a medical technology company focused ...

CHS is a condition marked by abdominal pain, nausea, and persistent vomiting linked to prolonged heavy cannabis use. This ...

HeartBeam, Inc. , a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that it will attend the JP Morgan 2026 Annual Healthcare ...

Background Ebstein’s anomaly (EA) exhibits significant anatomical and clinical heterogeneity, warranting a systematic ...

This technology from Corify Care records the heart’s electrical activity in real time, speeding diagnosis and improving ...

Stereotaxis plans to launch the MAGiC cardiac ablation catheter in early 2026, CEO and Chair David Fischel tells MassDevice.

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality globally. Effective management ...

Mount Sinai analysis looks at the effectiveness of electrocardiograms analyzed via deep learning as a tool for early COPD detection ...